Back to Search
Start Over
Carboplatin and vinorelbine in the treatment of advanced non-small-cell lung cancer: a multicenter phase II study.
- Source :
-
American journal of clinical oncology [Am J Clin Oncol] 1998 Feb; Vol. 21 (1), pp. 67-71. - Publication Year :
- 1998
-
Abstract
- The aim of this study was to identify a chemotherapy combination that would be active and well tolerated for palliative treatment of advanced non-small-cell lung cancer (NSCLC). From February 1992 to December 1994, a total of 77 patients affected by stage-IIIB and stage-IV NSCLC were treated with carboplatin 350 mg/m2 on day 1 and vinorelbine 25 mg/m2 on days 1 and 8 of each cycle, with cycles repeated every 28 days. All patients were evaluable for response and toxicity. A total of 24 patients showed a partial response (31% response rate; 95% CI = 21-41%). The median duration of overall survival was 41 weeks (95% CI = 31-51), and the median time to disease progression was 34 weeks (95% CI = 25-43). The treatment was well tolerated: no grade-4 toxicity was observed. The carboplatin-vinorelbine combination deserves to considered as a valid alternative to regimens that include cisplatin for palliative treatment of advanced NSCLC.
- Subjects :
- Adult
Aged
Carboplatin administration & dosage
Female
Humans
Male
Middle Aged
Survival Analysis
Vinblastine administration & dosage
Vinblastine analogs & derivatives
Vinorelbine
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Carcinoma, Non-Small-Cell Lung drug therapy
Lung Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0277-3732
- Volume :
- 21
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- American journal of clinical oncology
- Publication Type :
- Academic Journal
- Accession number :
- 9499262
- Full Text :
- https://doi.org/10.1097/00000421-199802000-00015